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comycin in the treatment of adult CDI patients. The analysis focused on three 
CDI patient subgroups: cancer, concomitant antimicrobials, and renal impaired 
patients. Methods: A Markov model was developed with a cycle length of 10 
days and a one year time horizon. The patient enters the model in the CDI health 
state and is treated with fidaxomicin, or vancomycin for 10 days. Health state 
utilities were derived from the literature. The model perspective was the Spanish 
health care provider. Deterministic and probabilistic sensitivity analyses were 
performed. Results: In all three CDI patient subgroups, fidaxomicin was domi-
nant compared to vancomycin. For cancer fidaxomicin resulted in cost savings of 
€ 2,397 with an incremental QALY gain of 0.016. For concomitant antibiotics fidax-
omicin resulted in cost savings of € 1,452 with an incremental QALY gain of 0.014. 
For renally impaired, fidaxomicin resulted in cost savings of € 1,432 and an incre-
mental QALY gain of 0.013. The main cost-effectiveness drivers were the recur-
rence rate and length of hospital stay. The probability of fidaxomicin being cost 
effective at the € 30,000 threshold was 96%, 94% and 96% respectively for cancer, 
concomitant antimicrobials and renal impairment, respectively. ConClusions: 
Fidaxomicin was dominant compared to vancomycin for these adult CDI patient 
subgroups.
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objeCtives: We aimed at estimating the impact of extending the French influ-
enza vaccination programme from at-risk/elderly (≥ 65 years) only, to additionally 
include children (2-17 years). Methods: A deterministic, age-structured, dynamic 
transmission model was used to simulate the transmission of influenza in the 
French population, under the current coverage with the trivalent inactivated vac-
cine (TIV) in at-risk/elderly individuals (= reference strategy) or after extending 
the coverage to healthy 2-17 years-old children with an intranasal, quadrivalent 
live-attenuated influenza vaccine (QLAIV) (= evaluated strategy). The transmis-
sion probabilities were determined using between-individuals contact patterns 
(“Polymod” matrix). Epidemiological, medical resources and costs data were issued 
by crossing data from literature and French resource-based value scales. The basic 
reproduction number (R0) of the model was calibrated to the observed numbers 
of influenza-like illness visits/year and deaths/year. The 10-year, undiscounted, 
number of symptomatic cases of confirmed influenza and direct medical costs 
(All-payer) were calculated for the 0-17 (direct effect) and ≥ 18 years-old (indirect 
effect). The incremental cost-effectiveness ratio (ICER) was calculated for the total 
population, using a 4% discount/year. Univariate and probabilistic sensitivity anal-
yses were performed. Results: Model calibration yielded R0= 1.27 (assuming 2.3 
million visits/year and 1,960 deaths/year). In the 0-17 years-old with 50% QLAIV 
coverage, the average number of confirmed influenza cases dropped by 865,000/
year, averting 58.4% of the cases occurring in the reference strategy and leading 
to 10-year savings of € 374 million. In the ≥ 18 years-old with unchanged TIV cover-
age, 1.2 million cases/year of confirmed influenza were averted (-27.6%), yielding 
additional 10-year savings of € 457 million. On average, 613 flu-related deaths were 
avoided annually. The ICER was € 18,000/life-year gained. The evaluated strategy 
was 98% cost-effective at a € 30,000/life-year gained threshold. ConClusions: The 
model demonstrated the direct and indirect benefits of protecting healthy children 
against influenza with QLAIV, on public health and economic outcomes in France.
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objeCtives: Multidrug-resistant tuberculosis (MDR-TB) is designated an orphan 
disease in Germany, where about ~65 patients are infected with multidrug-
resistant tuberculosis (MDR-TB). Regimens consisting of several drugs for up to 
24 months are the current standard of care (SoC) for treatment of MDR-TB. The 
aim of this analysis is to evaluate the costs and effectiveness of adding bedaqui-
line (BDQ) to a background regimen (BR) of the SoC in a German health care 
context. Methods: A cohort based Markov model was used to estimate cost-
effectiveness of bedaquiline plus background regimen (BDQ+BR) vs. BR alone for 
treatment of MDR- and XDR-TB (extensively drug resistant). The effectiveness 
of treatment was evaluated in QALYs, DALYs and life year gained (LYG). Inputs 
into the model were derived from a bedaquiline randomised, placebo controlled 
trial and from published literature. Drug costs (in 2014 euros) were taken from 
the German drug directory; a yearly discount rate of 3% was applied and a time 
horizon of 10 years was assumed. Sensitivity analyses were performed to evalu-
ate the impact of model parameters. Results: For a base-case analysis with a 
cohort of 65 MDR-TB patients, adding bedaquiline to BR results in higher costs 
compared to BR alone (4,5 vs. 2,4 MM € ), but yields better outcomes (66 QALYs 
gained). The incremental cost per QALY gained (ICER) was calculated as 33.357 
€ . For a cohort exclusively of XDR-TB patients, the ICER was calculated as 17.915 
€ . To evaluate the impact of model parameters, further sensitivity analyses were 
performed. ConClusions: Adding bedaquiline to a background regimen of anti-
TB drugs is cost-effective, probably even cost saving for patients with MDR- and 
XDR-TB, when compared to BR alone under different cost scenarios. Over a ten 
year period, cost savings were mostly achieved by lesser time of hospitalisation, 
although BDQ+BR drug costs are higher than BR alone.
and dominant in patients with a severe CDI recurrence from a Swedish health 
care perspective.
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objeCtives: Appropriate and timely empiric treatment is very essential for methi-
cillin-resistant Staphylococcus aureus (MRSA) -related infections. Inadequate empiric 
treatment is associated with increased mortality and longer hospital stay. This study 
compares economic impact of initial empiric linezolid (Emp-LIN) vs. vancomycin 
(Emp-VAN) vs. no empiric MRSA coverage (NE-MRSA) before culture-confirmed 
treatment, for suspected MRSA nosocomial pneumonia (NP). Methods: A 4 week 
decision model was developed capturing empiric, 1st and 2nd line therapy. Published 
literature and expert opinion provided clinical and resource use data, including 
efficacy, incremental mortality for NE-MRSA, adverse events, and length of hospital/
ICU stay. Cost and health utilities data were obtained from published literature. 
Base-case analysis used 2-day empiric, 10-day 1st/2nd-line treatment duration, 30% 
MRSA rate, and 1st line linezolid for NE-MRSA after culture confirmation. Patients 
with a negative culture for MRSA exited the model after empiric treatment, and 
were assigned a fixed cost for remaining treatment. Univariate and probabilistic 
sensitivity analyses were conducted. Costs were reported in 2014 USD. Results: 
Emp-LIN was associated with lower total costs ($41,975 vs. $42,288), and marginally 
greater QALY gain and overall treatment success compared to Emp-VAN, resulting in 
Emp-LIN ‘dominating’ Emp-VAN. Compared to NE-MRSA, Emp-LIN was more costly 
by $1,626, but had greater QALY gain (+0.836) and incremental treatment success 
(+5.9%), resulting in an incremental cost effectiveness ratio (ICER) of $1,946 per 
QALY gain, and $27,750 per successfully treated patient. Days in ICU stay, clinical 
efficacy, and MRSA rate had the greatest impact on ICER. Probability of Emp-LIN 
being cost-effective was 61% (vs. Emp-VAN) and 99% (vs. NE-MRSA) assuming a 
willingness-to-pay (WTP) of $50,000 per successfully treated patients and QALY gain 
respectively. ConClusions: Early treatment with Emp-LIN is a cost-effective alter-
native to Emp-VAN and NE-MRSA at reasonable WTP threshold, and should be con-
sidered a preferred treatment choice, especially at hospitals with high MRSA rate.
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objeCtives: Italian recommendations for human papillomavirus (HPV) immuni-
zation programmes currently target females only. However, males can be vectors 
in virus transmission and are at risk of disease infection. The BEST II study was 
designed to evaluate the cost-effectiveness (CE) of different interventions target-
ing females as well as males, and the economic impact of vaccination on a wide 
range of HPV-induced diseases. Methods: A dynamic Bayesian Markov model 
was developed to investigate HPV transmission between sexual partners and the 
cost-effectiveness of several HPV vaccination strategies. Both sexes were included 
in a universal vaccination programme which was compared to screening-only 
and female-only vaccination. A range of HPV-induced diseases was considered 
(cervical, vaginal, vulvar, anal, head/neck and penile cancer, the associated pre-
cancerous stages as well as anogenital warts). The process of sexual mixing was 
estimated based on age-, gender- and sexual behavioural-specific factors to esti-
mate the force of infection dynamically. The degree of susceptibility to the virus, 
associated with early sexual debut, high number of partners, smoking and previ-
ous STIs, was also included. We considered several scenarios; the baseline assumes 
universal vaccination to be implemented for 12-year-old females and males. The 
follow-up period was 55 years. Results: According to our preliminary analysis, 
universal vaccination resulted as a cost-effective alternative when compared to 
screening-only (with an incremental CE ratio, ICER, of € 1,200) and to female-only 
vaccination (ICER = € 6,900). We performed extensive sensitivity analyses to para-
metric assumptions, which confirmed the good CE profile of universal vaccination 
in Italy. ConClusions: Universal HPV vaccination of male and female cohorts is 
cost-effective compared to cervical screening and female-only vaccination, when 
accounting for a great variety of HPV-related diseases. This is mainly due to the 
fact that universal vaccination increases the effects of herd immunity and pro-
vides indirect protection against HPV.
PIN60
ecoNomIc eValuatIoN of fIdaxomIcIN for tHe treatmeNt of 
clostrIdIum dIffIcIle INfectIoNs (cdI) also KNowN as clostrIdIum 
dIffIcIle-assocIated dIarrHoea (cdad) IN sPaIN
Cobo Reinoso J.1, Grau Cerrato S.2, Mensa Pueyo J.3, Salavert Lletí M.4, Toledo A.5, Anguita P.5, 
Rubio-Terrés C.6, Rubio-Rodríguez D.6
1Infectious Diseases Department. Hospital Universitario Ramón y Cajal., Madrid, Spain, 
2Pharmacy Department. Hospital del Mar, Barcelona, Spain, 3Infectious Diseases Department. 
Hospital Clínic., Barcelona, Spain, 4Infectious Diseases Unit. Hospital La Fe., Valencia, Spain, 
5Astellas Pharma SA, Madrid, Spain, 6Health Value, Madrid, Spain
objeCtives: Fidaxomicin is the first in a new class of macrocylic antibiotics, 
indicated in adults for the treatment of Clostridium difficile infections (CDI). The 
objective was to analyse the cost-utility of fidaxomicin compared to oral van-
